Rehobot, Israel, February 22, 2023 /PR Newswire/ — cure responseis a commercial-stage precision oncology company and maker of the cResponse™ platform, an AI-driven functional genomics oncology drug prioritization technology, Clarit HMO will include cResponse in its “Oncology Services” package offered to its members announced that it had decided Premium collateral insurance (referred to as “Mushram Platinum”).
The cResponse platform combines rapid next-generation sequencing (NGS) with unique functional assays that assess cancer tissue response to various drugs and drug combinations while maintaining a functional tumor microenvironment (TME). I’m here. (PRNewsfoto/Curesponse)
Israeli Clarit Health Services is the world’s second largest HMO, providing 400 medical services through a nationwide network of 14 hospitals, 39 imaging centers, 1,400 clinics, 400 pharmacies, 37 children’s medical centers and 32 women’s medical centers. We provide superior patient care to over 10,000 members.
For over 100 years, Clarit has been at the forefront of medical and wellness innovation. Israel.
Approximately 60% of Clalit members have “Mushlam Platinum” supplemental health insurance, which entitles them to certain reimbursements for oncology services and products not regularly reimbursed by the Israeli Public Health Service. The Platinum Package now includes the cResponse Assay.
cResponse is an innovative platform that uniquely assesses how individual patient tumor tissue obtained by biopsy or surgery responds to various cancer treatments. This test is combined with rapid genomic analysis to optimally tailor treatment for each cancer patient.
“We are excited about Clalit’s decision to include cResponse testing in the package offered to members. It underscores what we offer as you navigate the difficult decision of whether to do what is best for each individual patient,” said Gil Rosen, Chief Operating Officer of Curesponse.
The cResponse test has already been reimbursed by private health insurance companies. IsraelClarit’s decision extends access to this technology to millions of cancer patients and upholds Curesponse’s mission to make cancer treatment choices truly personal.
Contact us for more information [email protected]
photograph – https://mma.prnewswire.com/media/1972847/cResponse.jpg
SOURCECure Response
